idarubicin has been researched along with Breast Cancer in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (39.34) | 18.7374 |
| 1990's | 19 (31.15) | 18.2507 |
| 2000's | 13 (21.31) | 29.6817 |
| 2010's | 5 (8.20) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barba, G; Cicconi, L; Divona, M; Falini, B; Hasan, SK; Lo-Coco, F; Mecucci, C; Metzler, M; Ottone, T | 1 |
| Guillen-Ponce, C; Molina-Garrido, MJ; Mora-Rufete, A | 1 |
| Gunduz, G; Gunduz, U; Keskin, T; Khodadust, R; Mutlu, P; Tansık, G; Unsoy, G; Yakar, A; Yalcin, S | 1 |
| Bonkovsky, HL; D'Agostino, RB; Hundley, WG; Jordan, JH; Lamar, ZS; Meléndez, GC; Poole, LB; Porosnicu, M; Vera, T; Whitlock, MC | 1 |
| Güç, E; Gündüz, G; Gündüz, U | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Delcambre, C; Delozier, T; Freyer, G; Genin, F; Lortholary, A; Piot, G; Pujade-Lauraine, E | 1 |
| Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M | 1 |
| Crivellari, D; Lombardi, D; Spazzapan, S; Toffoli, G; Veronesi, A | 1 |
| Gentilini, O; Goldhirsch, A; Martinelli, G; Peccatori, F | 1 |
| Cheng, CW; Ching Chan, S; Chow, LW; Ngor Wong, L; Tong, DK | 1 |
| Barbara, C; Bocci, G; Danesi, R; Del Tacca, M; Di Paolo, A; Fioravanti, A; Orlandi, P | 1 |
| Corona, G; Crivellari, D; Lestuzzi, C; Lombardi, D; Lucenti, A; Magri, MD; Massacesi, C; Sorio, R; Talamini, R; Toffoli, G; Veronesi, A | 1 |
| Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z | 1 |
| Cornblatt, B; Doyle, LA; Ross, DD; Tong, Y; Yang, W | 1 |
| Barron, JT; Ghalie, R; Kaizer, H; Kakavas, PW; Parrillo, JE | 1 |
| Robak, T | 1 |
| Alberto, P | 1 |
| Heinisch, H; Kerpel-Fronius, S | 1 |
| Barnadas, A; Casado, A; Clerigue, M; Cortés-Funes, H; Diaz-Rubio, E; García de Paredes, M; Jimeno, J; Mendiola, C; Rosell, R; Villar, A | 1 |
| Buckley, MM; Lamb, HM | 1 |
| Chawla, J; Fornari, FA; Gewirtz, DA; Orr, MS; Randolph, JK | 1 |
| Arnoldi, E; Barni, S; Bolognesi, A; Intini, C; Tabiadon, D; Zaniboni, A | 1 |
| Beijnen, JH; Boogerd, W; Tjahja, IS; van de Sandt, MM | 1 |
| Cilenti, G; Lelli, G; Suriano, A; Tartarone, A; Tozzi, L | 1 |
| Anderson, A; Cameron, DA; Howell, A; Leonard, RC; Ostrowski, J | 1 |
| Barats, JC; Bardonnet, M; Bergerat, JP; Borel, C; Chapelle-Marcillac, I; Deplanque, G; Dufour, P; Kurtz, JE; Mathelin, C; Poulin, G; Prévost, G | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
| Clowes, C; Duarte, R; Pu, QQ; Wang, X | 1 |
| Cersosimo, RJ | 1 |
| Amoroso, D; Bertelli, G; Gardin, G; Guido, T; Pennucci, C; Pronzato, P; Rosso, P | 1 |
| Carpano, S; Conti, EM; Di Lauro, L; Ganzina, F; Lopez, M; Natali, M; Vici, P | 1 |
| Kolarić, K; Mechl, Z | 1 |
| Bremer, K; Donhuijsen-Ant, R; Fritze, D; Klee, M; Possinger, K; Queisser, W; Rieche, K; Wagner, H; Westerhausen, M; Worst, P | 1 |
| Becchi, G; Cilenti, G; Farris, A; Guaraldi, M; Martoni, A; Pannuti, F; Piana, E; Saccani, F | 1 |
| Bastit, P; Chevallier, B; Hurteloup, P; Marty, M; Metz, R; Monnier, A; Namer, M; Roche, H | 1 |
| Bastholt, L; Dalmark, M; Gadeberg, CC; Jakobsen, A; Mouridsen, HT; Sandberg, E | 2 |
| Carpano, S; Contegiacomo, A; De Placido, S; Dello Ioio, C; Di Lauro, L; Fazio, S; Giannarelli, D; Lopez, M; Pagliarulo, C; Vici, P | 1 |
| Armand, JP; Bastit, P; Chevallier, B; de Oliveira, C; Hayat, M; Hurteloup, P; Keiling, R; Pourny, C; Schneider, M; Thomas, D | 1 |
| Bastholt, L; Dalmark, M; Ebbehøj, E; Elbaek, K; Jakobsen, A; Juul, P; Rasmussen, SN; Steiness, E | 1 |
| Ardizzoni, A; Conte, P; Fusco, V; Gulisano, M; Lionetto, R; Pronzato, P; Repetto, L; Rosso, R | 1 |
| Howell, A; Smith, DB | 2 |
| Raymond, V; Young, CW | 1 |
| Brandi, M; De Lena, M; Logroscino, A; Lorusso, V; Maiello, E; Paradiso, A | 1 |
| Bozzi, D; Brandi, M; Calabrese, P; De Lena, M; Romito, S | 1 |
| Blackledge, GR; Cullen, MH; Priestman, TJ; Stuart, NS; Tyrrell, CJ | 1 |
| Kolarić, K; Mechl, Z; Potrebica, V; Sopkova, B; Vukas, D | 1 |
| Angelelli, B; Camaggi, CM; Comparsi, R; Pacciarini, MA; Pannuti, F; Strocchi, E | 1 |
| Di Lauro, L; Di Pietro, N; Ganzina, F; Lazzaro, B; Lopez, M; Papaldo, P | 1 |
| Amoroso, D; Conte, PF; Lionetto, R; Pronzato, P; Rosso, R; Sertoli, MR | 1 |
| Bonadonna, G; Bonfante, V; Brambilla, C; Crippa, F; Ferrari, L; Rossi, A; Valagussa, P; Villani, F | 1 |
| Bastholt, L; Dalmark, M | 1 |
| Howell, A; Lucas, SB; Margison, JM; Smith, DB; Wilkinson, PM | 1 |
| Kolarić, K; Mechl, Z; Potrebica, V; Sopkova, B | 1 |
| Casper, ES; Currie, VE; Hakes, TB; Kaufman, RJ; Raymond, V | 1 |
| Di Pietro, N; Ganzina, F; Pacciarini, MA | 1 |
| Meyer, D; Nagel, GA; Schuff-Werner, P; Wander, HE | 1 |
| Martoni, A; Pacciarini, MA; Pannuti, F | 2 |
7 review(s) available for idarubicin and Breast Cancer
| Article | Year |
|---|---|
New oral drugs in older patients: a review of idarubicin in elderly patients.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Breast Neoplasms; Female; Humans; Idarubicin; Leukemia; Lymphoma; Male | 2004 |
[Clinical pharmacology of idarubicin].
Topics: Animals; Biological Availability; Breast Neoplasms; Female; Humans; Idarubicin; Leukemia; Lymphoma | 1993 |
[Oral idarubicin in treatment of advanced breast carcinoma].
Topics: Administration, Oral; Biological Availability; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin | 1996 |
Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Female; Humans; Idarubicin; Leukemia; Male | 1997 |
Idarubicin: an anthracycline antineoplastic agent.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Cytarabine; Drug Labeling; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1992 |
Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Topics: Aclarubicin; Anthraquinones; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Cell Survival; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Heart; Humans; Idarubicin; Leukemia; Menogaril; Mitoxantrone; Naphthacenes; Nogalamycin; Sarcoma; Structure-Activity Relationship | 1986 |
Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Topics: Administration, Oral; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Idarubicin; Infusions, Parenteral; Kinetics; Leukemia | 1986 |
17 trial(s) available for idarubicin and Breast Cancer
| Article | Year |
|---|---|
Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms; Comorbidity; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Neoplasm Metastasis; Neutropenia; Sepsis | 2004 |
Phase II study of an 'all-oral' regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer--safety, efficacy and quality of life.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Idarubicin; Middle Aged; Quality of Life; Survival Rate | 2005 |
Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Chromatography, High Pressure Liquid; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Idarubicin; Liver Neoplasms; Lung Neoplasms; Soft Tissue Neoplasms | 2006 |
Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Floxuridine; Humans; Idarubicin; Middle Aged; Prednimustine | 1993 |
Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Idarubicin; Middle Aged; Prednimustine; Treatment Outcome | 1997 |
Oral idarubicin and cyclophosphamide for metastatic breast cancer in elderly patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Female; Humans; Idarubicin; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Time Factors | 1998 |
Penetration of idarubicin into malignant brain tumor tissue.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Drug Administration Schedule; Glioblastoma; Humans; Idarubicin | 1999 |
Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Humans; Idarubicin; Leucovorin; Middle Aged; Tegafur | 1999 |
Idarubicin and cyclophosphamide--an active oral chemotherapy regimen for advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Fatigue; Female; Humans; Idarubicin; Infections; Middle Aged; Thrombocytopenia | 2000 |
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |
Oral chemotherapy with idarubicin plus cyclophosphamide in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Humans; Idarubicin; Middle Aged | 1991 |
Combination chemotherapy with oral idarubicin and cyclophosphamide for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Humans; Idarubicin; Middle Aged | 1991 |
Combination of idarubicin and cyclophosphamide administered orally in untreated postmenopausal breast cancer patients. A phase II study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged | 1991 |
Oral administration of idarubicin as first line cytostatic therapy in patients with metastasized breast cancer and favourable prognosis. A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society.
Topics: Administration, Oral; Aged; Breast Neoplasms; Combined Modality Therapy; Drug Evaluation; Female; Follow-Up Studies; Humans; Idarubicin; Middle Aged; Neoplasm Metastasis; Survival Rate | 1991 |
Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer.
Topics: Breast Neoplasms; Doxorubicin; Drug Evaluation; Female; Follow-Up Studies; Humans; Idarubicin; Menopause; Middle Aged; Neoplasm Metastasis | 1990 |
A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Heart; Humans; Idarubicin; Menopause; Middle Aged; Neoplasm Staging; Prospective Studies; Randomized Controlled Trials as Topic | 1989 |
The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Vomiting | 1985 |
37 other study(ies) available for idarubicin and Breast Cancer
| Article | Year |
|---|---|
Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23).
Topics: Antibiotics, Antineoplastic; Base Sequence; Breast Neoplasms; Carcinoma, Ductal, Breast; Chromosome Breakpoints; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Epirubicin; Female; Genetic Loci; Humans; Idarubicin; Leukemia, Biphenotypic, Acute; Leukemia, Promyelocytic, Acute; Middle Aged; Molecular Sequence Data; Multigene Family; Topoisomerase Inhibitors; Translocation, Genetic | 2014 |
Oral chemotherapy in elderly women with metastatic breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Idarubicin; Infusions, Intravenous; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2014 |
Idarubicin-loaded folic acid conjugated magnetic nanoparticles as a targetable drug delivery system for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Female; Folic Acid; Humans; Idarubicin; Magnetite Nanoparticles; MCF-7 Cells | 2014 |
Relation of Pre-anthracycline Serum Bilirubin Levels to Left Ventricular Ejection Fraction After Chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Bilirubin; Breast Neoplasms; Daunorubicin; Doxorubicin; Female; Hematologic Neoplasms; Humans; Idarubicin; Male; Middle Aged; Oxidative Stress; Retrospective Studies; Stroke Volume; Ventricular Dysfunction, Left | 2015 |
Fatty acid based hyperbranched polymeric nanoparticles for hydrophobic drug delivery.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Delayed-Action Preparations; Dendrimers; Drug Carriers; Drug Delivery Systems; Fatty Acids; Female; Humans; Hydrophobic and Hydrophilic Interactions; Idarubicin; Lipase; Nanoparticles; Polymers; Ricinoleic Acids; Tamoxifen | 2010 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoiesis; Humans; Idarubicin; Ifosfamide; Infections; Male; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2004 |
Chemotherapy during pregnancy: what is really safe?
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Fetal Diseases; Humans; Idarubicin; Maternal Exposure; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Treatment Outcome | 2004 |
Idarubicin and idarubicinol effects on breast cancer multicellular spheroids.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Inhibitory Concentration 50; Spheroids, Cellular; Time Factors | 2005 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Estrogens; Fatal Outcome; Female; Fluorouracil; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Mastectomy, Modified Radical; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nitriles; Radiotherapy, Adjuvant; Translocation, Genetic; Triazoles | 2006 |
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Breast Neoplasms; Cell Survival; Culture Media; Cyclosporine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Stability; HL-60 Cells; Humans; Idarubicin; Intracellular Fluid; Tumor Cells, Cultured | 1995 |
Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Doxorubicin; Echocardiography, Doppler, Color; Enalapril; Female; Gated Blood-Pool Imaging; Heart Failure; Humans; Idarubicin; Leukemia; Male; Middle Aged; Radiation Injuries; Radiotherapy; Ventricular Dysfunction, Left; Ventricular Function, Left | 1995 |
Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line.
Topics: Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Division; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Genes, myc; Humans; Idarubicin; Tumor Cells, Cultured | 1998 |
Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer.
Topics: Administration, Oral; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Treatment Outcome | 2000 |
Serum ICAM-1 concentrations following conventional dose consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell rescue.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Intercellular Adhesion Molecule-1; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Neutrophils; Recombinant Proteins; Solubility | 2000 |
Phase II study of oral idarubicin in elderly patients with advanced breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Idarubicin; Neutropenia; Remission Induction; Survival Rate; Thrombocytopenia | 1990 |
Weekly oral idarubicin in postmenopausal women with advanced breast cancer. A phase II study.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Idarubicin; Menopause; Middle Aged | 1990 |
Oral idarubicin in the treatment of advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Middle Aged | 1989 |
Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer. The Clinical Screening Group of the European Organization for Research and Treatment of Cancer.
Topics: Adult; Aged; Breast Neoplasms; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged | 1989 |
Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects.
Topics: Administration, Oral; Aged; Biological Availability; Breast Neoplasms; Daunorubicin; Half-Life; Humans; Idarubicin; Male; Middle Aged | 1989 |
Phase II trials of idarubicin, a new anthracycline.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Humans; Idarubicin; Lung Neoplasms; Male; Middle Aged | 1987 |
A phase II trial of oral idarubicin plus dibromodulcitol in advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged; Mitolactol; Neutropenia; Thrombocytopenia | 1989 |
Intravenous administration of cyclophosphamide, methotrexate and 5-fluorouracil in metastatic breast cancer. A pilot study.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Remission Induction; Soft Tissue Neoplasms | 1988 |
4-Demethoxydaunorubicin administered orally in advanced breast cancer. A phase II study.
Topics: Acute Kidney Injury; Administration, Oral; Adult; Aged; Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Daunorubicin; Female; Humans; Idarubicin; Middle Aged; Nausea; Soft Tissue Neoplasms; Stomach Ulcer; Vomiting | 1988 |
A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged | 1988 |
Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Drug Evaluation; Fluorouracil; Humans; Idarubicin; Methotrexate; Prednisone; Vincristine | 1988 |
Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Heart; Humans; Idarubicin; Kinetics; Melanoma | 1986 |
Phase II trial with oral idarubicin in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Middle Aged; Thrombocytopenia | 1986 |
Idarubicin in advanced breast cancer: a phase II study.
Topics: Aged; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Idarubicin; Middle Aged; Neoplasm Metastasis | 1986 |
New anthracycline analogs in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Idarubicin; Middle Aged; Naphthacenes | 1986 |
Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged | 1987 |
Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin.
Topics: Administration, Oral; Biological Availability; Breast Neoplasms; Daunorubicin; Drug Administration Schedule; Female; Humans; Idarubicin; Injections, Intravenous; Metabolic Clearance Rate | 1987 |
Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Idarubicin; Lymphatic Metastasis; Middle Aged; Remission Induction; Soft Tissue Neoplasms | 1987 |
A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Doxorubicin; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged | 1987 |
Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Carcinoma; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged | 1987 |
Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Neoplasm Metastasis | 1986 |
Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Daunorubicin; Female; Humans; Idarubicin; Male; Middle Aged | 1985 |